Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors
作者:Wufu Zhu、Chen Chen、Chengyu Sun、Shan Xu、Chunjiang Wu、Fei Lei、Hui Xia、Qidong Tu、Pengwu Zheng
DOI:10.1016/j.ejmech.2015.01.061
日期:2015.3
were 8.6, >5, 7.9 and 19.1 times more active than compound I (1.37 ± 0.07 μM, >10 μM, 9.52 ± 0.29 μM, 16.27 ± 0.54 μM), respectively. Structure–activity relationships (SARs) and docking studies indicated that the chromone moiety is necessary for the potent antitumor activity and cytotoxicity of these compounds. Substitution of the chromone moiety at the 6-position has a significant impact to the inhibitory
设计并合成了两个带有色酮部分的噻吩并嘧啶衍生物(10a - k,16a - j)。评价所有化合物在10uM浓度下对mTOR激酶的抑制活性。进一步评估了四种选择的化合物针对mTOR激酶,PI3Kα激酶和两种癌细胞系的IC 50值。一些目标化合物表现出中等至出色的mTOR /PI3Kα激酶抑制活性和细胞毒性。最有前途的化合物16i对mTOR /PI3Kα激酶表现出良好的抑制活性,对具有IC 50的H460和PC-3细胞系具有良好的抗肿瘤效力值分别为0.16±0.03μM,2.35±0.19μM,1.20±0.23μM和0.85±0.04μM,分别是化合物I活性的8.6,> 5、7.9和19.1倍(1.37±0.07μM,> 10μM,9.52±分别为0.29μM,16.27±0.54μM)。结构活性关系(SARs)和对接研究表明,色酮部分对于这些化合物的有效抗肿瘤活性和细胞毒性是必需的。色酮部